久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > ISCO
ISCO
ISCO ISCO

美國國際干細胞公司 International Stem Cell Corporation


The Company was founded for the specific purposes of solving key problems in the emerging field of regenerative medicine, cell availability and immune rejection. There are growing numbers of cell transplant therapies that have already been demonstrated to be effective in treating major diseases such as diabetes, liver disease and retinal disease, and many others. What is not available is a reliable, renewable and essentially unlimited source of human cells for use in these transplant procedures. Existing embryonic stem cell lines produce cells that will be difficult to match to the patient’s immune system. Parthenogenetic stem cells can solve both of these problems.

ISCO’s goal is to be the universal supplier of therapeutic cells for:

All developing embryonic stem cell based therapeutic procedures.
 

The medical/scientific research community.

To achieve these goals, ISCO has set three objectives:

To create an abundant source of parthenogenetic stem cells to meet the rapidly growing research and therapeutic demands of regenerative medicine and provide those cells to researchers entering clinical trials.
 

To create stem cell lines from unfertilized eggs, which would have all the benefits of human embryonic stem cells, but are superior in their ability to eliminate or diminish immune rejection in patients.
 

To build a true “Cell Bank” using its existing technology that will allow for on-demand delivery of cells that could be matched to the patient’s own immune system and reduce or eliminate the need for immunosuppressant drugs.

ISCO scientists are confident that we have now made the scientific breakthroughs that will meet these objectives. ISCO has created the world’s first human cell lines through the use of parthenogenesis and has already created the parthenogenetic stem cell line that matches the most common immune type in the US population. These parthenote cell lines will, we believe, be critical to open the pathway to successful stem cell therapy.
 

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 青青国产成人久久91网站站 | 亚洲欧美另类色图 | 亚洲第一区视频在线观看 | 一二三高清区线路1 | 国产99在线播放 | 亚洲欧美日韩网站 | 毛片免费网 | 欧美另类在线观看 | 香蕉啪啪 | 国产一区二区在线视频 | 欧美日韩一二三区 | 另类亚洲色图 | 亚洲自拍另类 | 亚洲另类第一页 | 91在线精品亚洲一区二区 | 国产欧美日本在线 | 欧美日韩亚洲区久久综合 | 不卡一区二区在线观看 | 亚洲 国产 日韩 欧美 | 毛片综合 | 美女网站全黄 | 亚洲欧美在线视频观看 | 亚洲国产成人综合精品2020 | bb毛片| 欧美第一页 | 久久91精品国产91 | 国产精品久久久久久久成人午夜 | 日韩h视频| 日本aⅴ在线 | 国产在线播放网站 | 亚洲国产天堂久久九九九 | h片在线播放 | 欧美日韩精品一区二区三区视频在线 | 国产国拍亚洲精品午夜不卡17 | 国产美女啪啪 | 国产精品久久久久久一级毛片 | 日韩最新视频一区二区三 | wwwxxx欧美| 亚洲小视频在线 | 国产传媒一区二区三区四区五区 | 国产一区精品在线观看 |